Urinary Bladder Cancer Clinical Trial
Official title:
Phase II Study of Neoadjuvant Toripalimab With Gemcitabine-Cisplatin in Subjects With T2-4aN0M0 Bladder Cancer: GZZJU-2021NB
This is a pre-surgical study involving subjects with local advanced bladder cancer, who are candidates for neoadjuvant therapy. It is a single-arm phase II portion.
Status | Recruiting |
Enrollment | 41 |
Est. completion date | April 3, 2025 |
Est. primary completion date | October 3, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients between 18 and 75 years old on day of signing informed consent, regardless of gender; - ECOG score 0-1 points, expected survival time> 6 months; - Pathologically confirmed locally advanced bladder urothelial carcinoma (cT2-T4a, N=1, M0, tumor staging according to American Joint Committee on Cancer (AJCC), 2017, eighth edition); - Appropriate and plan for radical cystectomy; - According to the RECIST1.1 standard, there is at least one measurable lesion (spiral CT scan =10mm); - Since the diagnosis of locally advanced bladder urothelial carcinoma, patient has not received anti-tumor system treatment; - The main organ functions are normal, and the following requirements must be met within 2 weeks before the first study treatment: - Routine blood examination must meet: WBC=4.0×109/L; PLT=90×109/L; Hb=90g/L (patients can be infused with red blood cells to meet this standard); - Blood biochemical examination must meet: serum creatinine (Cr) =1.5 times the upper limit of normal (ULN) or endogenous creatinine clearance =60mL/min; TBIL=1.5×ULN; ALB=30g/L; ALT and AST= 3.0×ULN; TSH=1.5×ULN. - Female patients with fertility must undergo a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they voluntarily adopt appropriate methods of contraception during the observation period and within 8 weeks after the last administration; - Agree to provide diagnosis and treatment-related tumor tissue specimens for clinical research, and have the ability to follow the planned research visit until the clinical recurrence/progress is clear. - Sign informed consent voluntarily. Exclusion Criteria: - Have previously received anti-PD1/PDL1/CTLA-4 antibody treatment or systemic chemotherapy, bladder infusion chemotherapy is excluded; - Have received bladder bacille Calmette Guerin (BCG) infusion therapy within 4 weeks; - Have received radiotherapy of the bladder in the past; - Patients with any history of active autoimmune disease or autoimmune disease; - Complicated diseases that require the use of immunosuppressive drugs; concurrent diseases that require the use of immunosuppressive agents for systemic or locally absorbable corticosteroids. It is forbidden to use prednisone greater than 10 mg/day or the same dose in the 2 weeks before the use of the study drug; - Combined with other malignant tumors; - Have a history of allergy to other antibody drugs; - The history of human immunodeficiency virus (HIV) infection; - The subject has active infection, including active tuberculosis; - Combined with severe heart disease, or combined with New York Heart Association (NYHA) grade 3 or 4 cardiac insufficiency; - Kidney transplant patients; |
Country | Name | City | State |
---|---|---|---|
China | Zhujiang Hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Zhujiang Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathological response rate evaluated after 4 cycles of neoadjuvant Toripalimab in combination with gemcitabine and cisplatin at time of radical cystectomy, each cycle is 21 days | the absence of residual muscle invasive bladder cancer in surgical specimens of cystectomy (pathologically decreased to =pT1N0, including pT0, pT1, pTa and pTis | Up to 90 days after last dose of investigation product | |
Secondary | Safety assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4 criteria | To assess safety of Toripalimab in combination with gemcitabine and cisplatin in patients with bladder cancer according to CTCAE v4 criteria | From the first day of the treatment to the end of neoadjuvant treatment, assessed up to 6 month | |
Secondary | Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 | From the start of neoadjuvant therapy to the time when any disease progression is first recorded, disease progression includes the progression detected by clinical or imaging before cystectomy, as well as the distant metastasis or pelvic recurrence after cystectomy. Newly discovered primary tumors in other parts of the urinary tract such as renal pelvis, ureter and urethra are not considered as disease progression. | From the start of neoadjuvant therapy to the time when any disease progression is first recorded. Assessed lasted for 24 months, calculated from the date of enrolled | |
Secondary | Tumor immune microenvironment indicators assessed by Microenvironment Analysis Panel | The expression rate of PDL1 in pathological specimens assessed by Burning Rock's product OncoScreen plus+Microenvironment Analysis Panel at the time of surgery | Assessed lasted for 24 months, calculated from the date of enrolled |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
Withdrawn |
NCT05335707 -
Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
|
||
Completed |
NCT03998579 -
Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04525781 -
Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
|
||
Completed |
NCT02897765 -
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT05822934 -
Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
|
Phase 3 | |
Completed |
NCT06156787 -
Patterns of Urinary Bladder Cancer in Darfur, Suda
|
||
Completed |
NCT02722538 -
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
|
Phase 1 | |
Completed |
NCT02437539 -
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 1 | |
Completed |
NCT02139371 -
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 0 | |
Completed |
NCT03433924 -
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
|
||
Active, not recruiting |
NCT03132922 -
MAGE-A4ᶜ¹º³²T for Multi-Tumor
|
Phase 1 | |
Completed |
NCT05946369 -
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
|
||
Completed |
NCT00462488 -
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
|
Phase 2 | |
Recruiting |
NCT05621837 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
||
Recruiting |
NCT05644041 -
Intravesical Gemcitabine in Patients With NMIBC
|
Phase 2 | |
Completed |
NCT04635566 -
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute
|
N/A | |
Completed |
NCT01836978 -
Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
|
N/A | |
Terminated |
NCT01374789 -
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
|
Phase 2 | |
Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 |